ISOBM

INTERNATIONAL SOCIETY OF ONCOLOGY AND BIOMARKERS

14 City Quay, Dundee
DDI 3JA
Scotland
office@isobm.org

ISOBM Webinars 2026 – https://www.isobm.org/

General information: Thursdays, 16:00 – 17:00 Central European Time

Month	Topic	Lecturer(s)
January 22th, 2026	**Young Scientist/Poster Award from 2025 ISOBM scientific meeting in Murnau** Moderator: Vathany Kulasingam Registration link	**Christian Grätz,** **Ferdinand Willem Janssen,** **Carsten Uhlig,** **Eleni Polatoglou**
March 26th, 2026	**Tumor markers; identifying pre-analytical, analytical and post-analytical challenges and opportunities to improve the clinical cancer care** Moderator: Vathany Kulasingam Registration link	**Huub van Rossum**, Netherlands Cancer Institute, Amsterdam, The Netherlands
May 21st, 2026	**The GenomeMET project: Routes for standardization of circulating tumour DNA testing** Moderator: Huub van Rossum Registration link	**Alison Devonshire,** National Measurement Laboratory, Surrey, UK
June 25th, 2026	**Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer** Moderator: Huub van Rossum Registration link	**Myriam Chalabi**, Netherlands Cancer Institute, Amsterdam, The Netherlands
September 10th, 2026	**Illuminating the Cancer Journey with Cell-Free Whole Genome Sequencing** Moderator: Vathany Kulasingam Registration link	**Trevor Pugh,** University Health Network and University of Toronto, Canada
November 26th, 2026	**Pancreatic Cancer – Early Detection Using Lipid Profiling** Moderator: Radek Kucera Registration link	**Michal Holcapek,** Faculty of Chemical Technology, University of Pardubice, Czech Republic

Background

January 22th: Young scientist/poster award from 2025 ISOBM scientific meeting in Murnau

Christian Grätz - Cell-free RNA biomarkers for off-label therapy monitoring of anaplastic thyroid cancer *in vitro*
Ferdinand Willem Janssen - Identification and validation of liquid biopsy-based methylation biomarkers: a germ cell tumor subtype-specific study
Carsten Uhlig - Systematic Framework for Preparing cfDNA Methylation Features for Machine Learning-Based Detection of Pancreatic Cancer
Eleni Polatoglou - Comparison of four methods for characterization of methylation patterns on cell-free DNA in blood plasma

March 26th: Tumor markers; identifying pre-analytical, analytical and post-analytical challenges and opportunities to improve the clinical cancer care

Tumor markers are common test to support the clinical cancer care. Challenges and new opportunities will be presented based on the three clinical laboratory phases. Pre-analytical issues discussed will include self-collection of blood for tumor marker analysis and analyte stability. Analytical challenges relate to the (lack of) harmonization and work done by the IFCC and ISOBM working group on tumor marker harmonization (WG-TMH) to address this. Finally, as post-analytical opportunity, developments in the clinical interpretation and modelling of longitudinal changes of tumor marker results, will be presented.

May 21th: The GenomeMET project: Routes for standardization of circulating tumour DNA testing

Liquid biopsies are being rapidly translated into clinical testing and longitudinal monitoring of cancer patients, however approaches to evaluate accuracy and comparability of workflows for circulating tumour DNA (ctDNA) analysis are lagging behind. This talk will explore routes to standardise measurements of ctDNA such as variant allelic frequency and support QC/QA of workflows including cell-free DNA extraction and total DNA quantification. Reference methods, reference materials and routes for calculating measurement uncertainty developed through the EU GenomeMET project will be discussed.

June 25th: Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer

A short course of immunotherapy was found to be highly effective in a subset of patients with colon cancer. The treatment, which consisted of two cycles of immunotherapy prior to surgery, was effective in almost all patients. In two third of patients, there were no longer any live tumor cells at the time of surgery. The patients' immune system had cleaned up the cancer cells. These groundbreaking discoveries were made as part of the NICHE-2 trial at the Netherlands Cancer Institute and have been published in the ***New England Journal of Medicine***.

September 10th: Illuminating the Cancer Journey with Cell-Free Whole Genome Sequencing

Follows…

November 26th: Pancreatic Cancer – Early Detection Using Lipid Profiling

Follows…